REASONS FOR THERAPEUTICAL FAILURE IN TREATMENT OF HELICOBACTER PYLORI INFECTION AND THERAPEUTIC POSSIBILITIES
Abstract
Background. Helicobacter pylori infection is the main cause of gastritis, gastric and duodenal ulcer and MALT lymphoma. Bacteria is also recognised as a risk for the development of gastric cancer. More than half of the world population and also Slovenian population is infected with H. pylori. Bacteria causes serious diseases only in about 20% of infected who are candidates for the eradication therapy. The basic therapeutic combination is a proton pump inhibitor with two antibiotics. Because of the emerging bacterial resistance to antibiotics we are forced to find new therapeutical possibilities. The main reasons for therapeutic failure are described in the article as well as data for antimicrobial resistance in Slovenia.
Conclusions. Recommended management strategies in Europe and in Slovenia are described. Eradication success is lower than it was and we should always test for successful eradication by urea breath test or endoscopic based tests if endoscopy is clinically indicated. Management strategies in case of therapeutical failure are also described.
Downloads
References
European Helicobacter Pylori Study Group. Current European concepts in the management of Helicobacter pylori infecton. The Maastricht Consensus Report. Gut 1997; 41: 8–13.
IARC Working Group on the evaluation of carcinogenic risks to humans. Helicobacter pylori. In: Schistosomes, liver flukes and Helicobacter pylori: views and expert opinions of an IARC Working Group on the evaluation on carcinogenic risks to humans. Lyon, IARC 1994: 177–240.
Figueredo C, Machado JC, Phoroah P et al. Helicobacter pylori and interleukin 1 genotyping: an opportunity to identify high risk individuals for gastric carcinoma. J Natl Cancer Inst 2002; 94: 1680–7.
Tepeš B, Križman I. Priporočila za zdravljenje okužbe z bakterijo Helicobacter pylori v Sloveniji. Zdrav Vestn 1998; 67: 159–62.
Malfertheiner P, Megraud F, O’Morain C et al. Current concepts in the management of Helicobacter pylori infection. The Maastricht 2-2000 Consensus Report. Aliment Pharmacol Ther 2002; 16: 167–80.
NIH consensus conference. Helicobacter pylori in peptic ulcer disease. JAMA 1994; 272: 65–9.
Tepeš B, Kavčič B. Our experience in eradication of Helicobacter pylori in patients with chronic ulcer disease and preliminary results of more than one year follow-up. Acta Gastro-Enterologica Belgica 1993; 56: 154–4.
Lind T, Veldhuysen van Zenten S, Unge P et al. Eradication of Helicobacter pylori using one-week triple therapies combining omeprazole with two antimicrobials. The MACH 1 study. Helicobacter 1996; 1: 138–44.
Moayyedi P, Feltbower R, Crocombe W et al. The effectiveness of omeprazole, clarithromycin and tinidazole in eradicating Helicobacter pylori in a community screen and treat programme. Leeds Help Study Group. Aliment Pharmacol Ther 2001; 15: 403–9.
Ulmer HJ, Beckerling A, Gatz G. Recent use of proton pump inhibitor-based triple therapies for the eradication of H. pylori: a broad data review. Helicobacter 2003; 8: 95–104.
Tepeš B. Primerjava dveh tritirnih antimikrobnih shem zdravljenja okužbe z bakterijo Helicobacter pylori. Zdrav Vestn 2000; 69: 505–8.
Broutet N, Tehamgoue S, Pereira E, Lamonliatte H, Salamon R, Megraud F. Risk factors for failure of Helicobacter pylori therapy. Results of an individual data analysis of 2751 patients. Aliment Pharmacol Ther 2003; 17: 99–109.
Tepeš B, Gubina M, Kavčič B, Košutić D, Križman I, Ihan A. Prospektivna kontrolirana študija zdravljenja bolnikov s Helicobacter pylori pozitivno ulkusno boleznijo dvanajstnika. Zdrav Vestn 1995; 64. 687–91.
Megraud F. Helicobacter pylori and macrolides. In: Schönfeld W, Kirst HA eds. Macrolide antibiotics. Berlin: Birkhauser, 2002; 243–60.
Bazzoli F, Berretti D, De Luca L et al. What can be learnt from the new data about antibiotic resistance? Are there any practical clinical consequences of Helicobacter pylori antibiotic resistance? Eur J Gastroenterol Hepatol 1999; 11: Suppl 2: S 39–42.
Lind T, Megraud F, Unge P et al. The MACH 2 study – role of omeprazole in eradication of Helicobacter pylori with one-week triple therapies; a randomised double-blind study. Gastroenterology 1999; 116: 248–53.
Walt PR. Metronidazole resistant H. pylori of questionable clinical importance. Lancet 1995; 348: 489–90.
Lamarque D, Tankovic J, Berrhouma A et al. Triple therapy using ciprofloxacin for eradication of clarythromycin and metronidazole-resistant Helicobacter pylori. Gut 1997; 419: Suppl 1: A 104.
Perri F, Festa V, Merla A, Quitadomo M, Clemente R, Andriulli A. Amoxicillin/tetracycline combinations are inadequate as alternative therapies for Helicobacter pylori infection. Helicobacter 2002; 7: 99–104.
Gubina M, Tepeš B, Gorenšek M, Križman I, Ihan A, Poljak M. Sensitivity of Helicobacter pylori to eight antibiotics. The 5th International Conference of the Macrolides, Azolides, Streptogromines and Ketolides. Sevilla 2000: 86.
Skvarč M, Ećimović K. Primerjava občutljivosti bakterije Helicobacter pylori za antibiotike z agar dilucijsko metodo in E-testom. Ljubljana: Medicinska fakulteta, 2001: 1–38.
Goodwin CS, McNulty CAM. Bacteriological and pharmacological basis for the treatment of Helicobacter pylori infection. In: Rathborne BJ, Healthy RU eds. Helicobacter pylori and gastroduodenal disease, 2nd ed. Oxford: Blackwell Scientific Publications, 1992: 224–31.
Fatura T, Shirai N, Xiao F, Okashi K, Ishizaki T. Effect of high-dose lansopresole on intragastric pH in subjects who are homozygous extensive metabolizers of cytochrome P4502C19. Clin Pharmacol Ther 2001; 70: 484–92.
Mashkowitz M, Konihoff FM, Peled Y et al. High Helicobacter pylori numbers are associated with low eradication rate after triple therapy. Gut 1995; 36: 845–7.
Masconi G, Parente F, Russo A, Vago L, Imbesi V, Porro GB. Do some patients with Helicobacter pylori infection benifit from an extension to 2 weeks of a proton pump inhibitor-based triple eradication therapy? Am J Gastroenterol 2001; 96: 356–66.
Amieva MR, Salama NR, Tomphins LS, Falkow S. Helicobacter pylori enter and survive within multivesicular vacuoles of epithelial cells. Cell Microbiol 2002; 4: 677–90.
Cellini L, Allocati N, Angelucci D et al. Coccoid Helicobacter pylori not culturable in vitro reverts in mice. Microbiol Immunol 1994; 38: 843–50.
Kusters JG, Gerrits MM, Van Strijp JA, Vandenbrocke Grouls CM. Coccoid forms of Helicobacter pylori are the morphologic manifestation of cell death. Infect Immun 1997; 65: 3572–9.
Ihan A, Tepeš B, Kavčič B, Gubina M. IL-2 receptor expression on gastric mucosa T lymphocytes is enhanced in duodenal ulcer patients compared with non-ulcer dyspeptic patients. Hepato-Gastroenterology 1996; 43: 1665–70.
Borody T, Ren Z, Pang G, Cloncy R. Impaired host immunity contributes to Helicobacter pylori eradication failure. Am J Gastroenterol 2002; 97: 3032–7.
Tepeš B, Kavčič B, Gubina M, Križman I. A four-year follow-up of duodenal ulcer patients after Helicobacter pylori eradication. Hepato-Gastroenterology 1999; 46: 1746–50.
Wang WM, Gu Q, Lam SK et al. Randomised controlled study of robeprazole, levofloxacin and rifabutin triple therapy vs. quadruple therapy as second-line treatment for Helicobacter pylori infection. Aliment Pharmacol Ther 2003; 17: 553–60.
Coelho LG, Martins GM, Passos MC et al. Once-daily, low cost, highly effective Helicobacter pylori treatment to family members of gastric cancer patients. Aliment Pharmacol Ther 2003; 17: 131–6.
Zullo A, Vaira D, Vakil N et al. High eradication rates of Helicobacter pylori with a new sequential treatment. Aliment Pharmacol Ther 2003; 17: 719–26.
Jaup BH. Dual »rescue« therapy for eradication of H. pylori in previous triple therapy failure. Gut 1999; 45: A 118.
Colvet X, Garcia N, Lopez T et al. A meta analysis of short versus long therapy with a proton pump inhibitor, clarithromycin and either metronidazole or amoxicillin for treating Helicobacter pylori infection. Aliment Pharmacol Ther 2000; 14. 603–9.
Gubina M, Newell DG, Hawthin PR, Avšič-Županc T, Križman I. Helicobacter pylori IgG in our assimptomatic Slovenian population. Zdrav Vestn 1991; 60: 449–52.
Tepeš B. Helicobacter pylori. Krka Med Farm 1999; 20: Suppl 1: 1–55.
Tepeš B, Kavčič B, Zaletel KL, Gubina M, Ihan A, Poljak M, Križman I. Twoto four year histological follow-up of gastric mucosa after Helicobacter pylori eradication. J Pathol 1999; 188: 24–9.
Tepeš B, Križman I, Gorenšek M, Gubina M, Orel I. Is a one-week course of triple anti Helicobacter pylori therapy sufficient to control active duodenal ulcer. Aliment Pharmacol Ther 2001; 7: 1037–45.
The Author transfers to the Publisher (Zdravniški vestnik/Slovenian Medical Journal) all economic copyrights following form Article 22 of the Slovene Copyright and Related Rights Act (ZASP), including the right of reproduction, the right of distribution, the rental right, the right of public performance, the right of public transmission, the right of public communication by means of phonograms and videograms, the right of public presentation, the right of broadcasting, the right of rebroadcasting, the right of secondary broadcasting, the right of communication to the public, the right of transformation, the right of audiovisual adaptation and all other rights of the author according to ZASP.
The aforementioned rights are transferred non-exclusively, for an unlimited number of editions, for the term of the statutory
The Author can make use of his work himself or transfer subjective rights to others only after 3 months from date of first publishing in the journal Zdravniški vestnik/Slovenian Medical Journal.
The Publisher (Zdravniški vestnik/Slovenian Medical Journal) has the right to transfer the rights, acquired parties without explicit consent of the Author.
The Author consents that the Article be published under the Creative Commons BY-NC 4.0 (attribution-non-commercial) or comparable licence.
